Cargando…

The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review

Gastric cancer (GC) is a disease with macromolecular phenotypic heterogeneity and poor prognosis, especially for metastatic GC (mGC). Chemotherapy is the first choice for second-line treatment. However, the benefits of second-line chemotherapy are limited, so there is an urgent need for new treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinwei, Zeng, Yun, Zhang, Junling, Huang, Mengli, Yin, Bijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304692/
https://www.ncbi.nlm.nih.gov/pubmed/35875121
http://dx.doi.org/10.3389/fonc.2022.940263
_version_ 1784752147008585728
author Wang, Xinwei
Zeng, Yun
Zhang, Junling
Huang, Mengli
Yin, Bijian
author_facet Wang, Xinwei
Zeng, Yun
Zhang, Junling
Huang, Mengli
Yin, Bijian
author_sort Wang, Xinwei
collection PubMed
description Gastric cancer (GC) is a disease with macromolecular phenotypic heterogeneity and poor prognosis, especially for metastatic GC (mGC). Chemotherapy is the first choice for second-line treatment. However, the benefits of second-line chemotherapy are limited, so there is an urgent need for new treatment regimens to improve patient outcomes. A 65-year-old man with mGC was HER-2 positive. Standard trastuzumab, combined with chemotherapy, was given in the first-line therapy and progression-free survival (PFS) was 8 months. Second-line treatment with pyrotinib in combination with trastuzumab and chemotherapy yielded a PFS of 20 months, in sharp contrast to a median survival of 2.9-6.2 months for a majority of advanced GC patients. This case provides a meaningful reference for the second-line treatment of mGC patients with HER-2 positive. This case also provides valuable information on the response to pyrotinib plus trastuzumab of patients with brain metastases and a better understanding of dual target combination therapy applications in the future.
format Online
Article
Text
id pubmed-9304692
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93046922022-07-23 The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review Wang, Xinwei Zeng, Yun Zhang, Junling Huang, Mengli Yin, Bijian Front Oncol Oncology Gastric cancer (GC) is a disease with macromolecular phenotypic heterogeneity and poor prognosis, especially for metastatic GC (mGC). Chemotherapy is the first choice for second-line treatment. However, the benefits of second-line chemotherapy are limited, so there is an urgent need for new treatment regimens to improve patient outcomes. A 65-year-old man with mGC was HER-2 positive. Standard trastuzumab, combined with chemotherapy, was given in the first-line therapy and progression-free survival (PFS) was 8 months. Second-line treatment with pyrotinib in combination with trastuzumab and chemotherapy yielded a PFS of 20 months, in sharp contrast to a median survival of 2.9-6.2 months for a majority of advanced GC patients. This case provides a meaningful reference for the second-line treatment of mGC patients with HER-2 positive. This case also provides valuable information on the response to pyrotinib plus trastuzumab of patients with brain metastases and a better understanding of dual target combination therapy applications in the future. Frontiers Media S.A. 2022-07-08 /pmc/articles/PMC9304692/ /pubmed/35875121 http://dx.doi.org/10.3389/fonc.2022.940263 Text en Copyright © 2022 Wang, Zeng, Zhang, Huang and Yin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Xinwei
Zeng, Yun
Zhang, Junling
Huang, Mengli
Yin, Bijian
The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
title The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
title_full The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
title_fullStr The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
title_full_unstemmed The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
title_short The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
title_sort durable effect of pyrotinib plus trastuzumab and chemotherapy in her2-positive gastric cancer with brain metastases: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304692/
https://www.ncbi.nlm.nih.gov/pubmed/35875121
http://dx.doi.org/10.3389/fonc.2022.940263
work_keys_str_mv AT wangxinwei thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview
AT zengyun thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview
AT zhangjunling thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview
AT huangmengli thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview
AT yinbijian thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview
AT wangxinwei durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview
AT zengyun durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview
AT zhangjunling durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview
AT huangmengli durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview
AT yinbijian durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview